Mediar Therapeutics CEO Rahul Ballal (L) and CSO Paul Yaworsky
March 15, 2023 01:30 AM EDT
Financing
Startups

Five phar­mas back $85M Se­ries A for Me­di­ar's fi­bro­sis-mod­u­lat­ing an­ti­bod­ies

Kyle LaHucik

Senior Reporter

Me­di­ar Ther­a­peu­tics nabbed $85 mil­lion to get in the clin­ic next year with its first an­ti­body meant to mod­u­late fi­bro­sis, hence the biotech’s name …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times